PMID- 33648413
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20220531
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 62
IP  - 8
DP  - 2021 Aug
TI  - Expression levels of HLA-DR in acute myeloid leukemia: implications for 
      antigenicity and clinical outcome.
PG  - 1907-1919
LID - 10.1080/10428194.2021.1885659 [doi]
AB  - Low human leukocyte antigen (HLA)-DR expression might compromise CD4(+) 
      T-cell-mediated anti-tumor immunity. Its immunological and clinical significance 
      however remain undefined in non-promyelocytic acute myeloid leukemia (AML). 
      Taking advantage of mass spectrometry-based immunopeptidome analysis of primary 
      AML samples (n = 31), we studied the implications of low HLA-DR expression for 
      antigen presentation and analyzed its association with disease characteristics 
      and survival within a cohort of 399 AML patients. Remarkably, overall HLA-DR/DQ 
      immunopeptidome diversity was preserved in AML with low HLA-DR expression 
      (HLA-DR(low) AML) and was associated with a shift in HLA-DR/DQ allotype 
      abundances (HLA-DQ to HLA-DR/DQ ligand ratio 0.36 vs 0.19 in HLA-DR(low) and 
      HLA-DR(high) patients, respectively). Consistent with unimpaired antigenicity, 
      survival was similar in HLA-DR(low) and HLA-DR(high) patients. Demonstrating for 
      the first time that overall HLA-DR/DQ antigen presentation is preserved in 
      HLA-DR(low) AML, our findings provide a rationale for the non-inferior outcome 
      observed in HLA-DR(low) AML patients.
FAU - Roerden, Malte
AU  - Roerden M
AUID- ORCID: 0000-0001-7283-9778
AD  - Department of Hematology, Oncology, Clinical Immunology and Rheumatology, 
      University Hospital Tubingen, Tubingen, Germany.
AD  - Institute for Cell Biology, Department of Immunology, University of Tubingen, 
      Tubingen, Germany.
AD  - Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed 
      Tumor Therapies", University of Tubingen, Tubingen, Germany.
FAU - Marklin, Melanie
AU  - Marklin M
AUID- ORCID: 0000-0002-2920-3894
AD  - Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed 
      Tumor Therapies", University of Tubingen, Tubingen, Germany.
AD  - Clinical Collaboration Unit Translational Immunology, German Cancer Consortium 
      (DKTK), Department of Internal Medicine, University Hospital Tubingen, Tubingen, 
      Germany.
FAU - Salih, Helmut R
AU  - Salih HR
AD  - Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed 
      Tumor Therapies", University of Tubingen, Tubingen, Germany.
AD  - Clinical Collaboration Unit Translational Immunology, German Cancer Consortium 
      (DKTK), Department of Internal Medicine, University Hospital Tubingen, Tubingen, 
      Germany.
FAU - Bethge, Wolfgang A
AU  - Bethge WA
AD  - Department of Hematology, Oncology, Clinical Immunology and Rheumatology, 
      University Hospital Tubingen, Tubingen, Germany.
FAU - Klein, Reinhild
AU  - Klein R
AD  - Department of Hematology, Oncology, Clinical Immunology and Rheumatology, 
      University Hospital Tubingen, Tubingen, Germany.
FAU - Rammensee, Hans-Georg
AU  - Rammensee HG
AD  - Institute for Cell Biology, Department of Immunology, University of Tubingen, 
      Tubingen, Germany.
AD  - Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed 
      Tumor Therapies", University of Tubingen, Tubingen, Germany.
AD  - German Cancer Consortium (DKTK), DKFZ partner site Tubingen, Tubingen, Germany.
FAU - Nelde, Annika
AU  - Nelde A
AUID- ORCID: 0000-0001-8504-8481
AD  - Institute for Cell Biology, Department of Immunology, University of Tubingen, 
      Tubingen, Germany.
AD  - Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed 
      Tumor Therapies", University of Tubingen, Tubingen, Germany.
AD  - Clinical Collaboration Unit Translational Immunology, German Cancer Consortium 
      (DKTK), Department of Internal Medicine, University Hospital Tubingen, Tubingen, 
      Germany.
FAU - Walz, Juliane S
AU  - Walz JS
AUID- ORCID: 0000-0001-6404-7391
AD  - Institute for Cell Biology, Department of Immunology, University of Tubingen, 
      Tubingen, Germany.
AD  - Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed 
      Tumor Therapies", University of Tubingen, Tubingen, Germany.
AD  - Clinical Collaboration Unit Translational Immunology, German Cancer Consortium 
      (DKTK), Department of Internal Medicine, University Hospital Tubingen, Tubingen, 
      Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210302
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (HLA-DR Antigens)
SB  - IM
MH  - Antigen Presentation
MH  - *HLA-DR Antigens/genetics
MH  - Humans
MH  - *Leukemia, Myeloid, Acute/diagnosis/genetics
OTO - NOTNLM
OT  - AML
OT  - Acute myeloid leukemia
OT  - HLA class II
OT  - HLA-DR
OT  - immunopeptidome
OT  - mass spectrometry
EDAT- 2021/03/03 06:00
MHDA- 2021/08/17 06:00
CRDT- 2021/03/02 05:42
PHST- 2021/03/03 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2021/03/02 05:42 [entrez]
AID - 10.1080/10428194.2021.1885659 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2021 Aug;62(8):1907-1919. doi: 10.1080/10428194.2021.1885659. Epub 
      2021 Mar 2.